Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391762 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL418425 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL10098821 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL5391765 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL5395653 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL1697179 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL5395648 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL5385053 | 0.99 | ALDH1A1 (0.98) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL5388340 | 0.99 | ALDH1A1 (0.98) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL5388335 | 0.99 | ALDH1A1 (0.98) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584715-B2 | Crystalline form of sofpironium bromide and preparation method thereof | BOTANIX SB, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11566000-B2 | Crystalline form of sofpironium bromide and preparation method thereof | BOTANIX SB, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11352323-B2 | Processes for making, and methods of using, glycopyrronium compounds | JOURNEY MEDICAL CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220118236-A1 | ROLL-ON APPLICATORS AND METHODS FOR TREATING DERMAL CONDITIONS | SWK FUNDING LLC | 2022-04-21 | — | — | US | disclosed |
| US-20210395197-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| US-20210171460-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210130289-A1 | PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS | SWK FUNDING LLC | 2021-05-06 | — | — | US | disclosed |
| US-10906871-B2 | Processes for making, and methods of using, glycopyrronium compounds | DERMIRA, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2020235665-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-11-26 | — | — | WO | disclosed |
| US-20190161443-A1 | PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS | SWK FUNDING LLC | 2019-05-30 | — | — | US | disclosed |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-10-02 | — | — | US | disclosed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | disclosed |
| US-7417147-B2 | muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-08-26 | — | — | US | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-7399861-B2 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2008-07-15 | — | — | US | disclosed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | BODOR LABORATORIES, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130289-A1 | PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS | GYPA, TPO, CYP21A2 | ALDH1A1 2560/4885CYP1A2 523/4885CYP3A4 318/4885 |
| US-11584715-B2 | Crystalline form of sofpironium bromide and preparation method thereof | POLR2B, COPB2, FXR1 | ALDH1A1 4690/4885CYP1A2 1769/4885CYP3A4 535/4885 |
| US-11566000-B2 | Crystalline form of sofpironium bromide and preparation method thereof | POLR2B, COPB2, FXR1 | ALDH1A1 4682/4885CYP1A2 1806/4885CYP3A4 553/4885 |
| US-20080027091-A1 | e.g. 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, ADRB2, ADRB1 | ALDH1A1 1867/4885CYP1A2 1405/4885CYP3A4 1722/4885 |
| US-20080242651-A1 | 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(carboxymethyl)-1-methylpyrrolidinium inner salt; muscarinic receptor antagonist; chronic obstructive pulmonary disease or asthma; synergistic mixture with antiinflammatory corticosteroid, betamimetic agent or antiallergic agent | CHRM2, CHRM1, CHRM3 | ALDH1A1 1752/4885CYP1A2 1678/4885CYP3A4 1898/4885 |
| US-20210171460-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | POLR2B, COPB2, FXR1 | ALDH1A1 4682/4885CYP1A2 1806/4885CYP3A4 553/4885 |
| US-11352323-B2 | Processes for making, and methods of using, glycopyrronium compounds | GYPA, TPO, CYP21A2 | ALDH1A1 2560/4885CYP1A2 523/4885CYP3A4 318/4885 |
| US-10906871-B2 | Processes for making, and methods of using, glycopyrronium compounds | GYPA, TPO, CYP21A2 | ALDH1A1 2560/4885CYP1A2 523/4885CYP3A4 318/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | ALDH1A1 696/4885CYP1A2 520/4885CYP3A4 1136/4885 |
| US-20210395197-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | POLR2B, COPB2, FXR1 | ALDH1A1 4690/4885CYP1A2 1769/4885CYP3A4 535/4885 |
| US-20190161443-A1 | PROCESSES FOR MAKING, AND METHODS OF USING, GLYCOPYRRONIUM COMPOUNDS | GYPA, TPO, CYP21A2 | ALDH1A1 2560/4885CYP1A2 523/4885CYP3A4 318/4885 |
| US-20220118236-A1 | ROLL-ON APPLICATORS AND METHODS FOR TREATING DERMAL CONDITIONS | SLC18A3, ACHE, CUTA | ALDH1A1 148/4885CYP1A2 408/4885CYP3A4 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.